Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency.
Activation of resting T cells induces the synthesis of interleukin-2 (IL-2) and expression of its high-affinity receptor that involves both a 55-kDa IL-2 binding peptide identified by the anti-Tac monoclonal antibody and a 75-kDa IL-2 binding peptide associated in a receptor complex. The IL-2 receptor is proving to be an extraordinarily important therapeutic target since it is expressed by the abnormal T cells in patients with certain lymphoid malignancies or autoimmune disorders and in individuals rejecting allografts whereas it is not expressed by normal resting cells. IL-2 receptor directed monoclonal antibodies, genetically engineered humanized antibodies, and antibodies armed with toxins or radionuclides represent novel therapeutic agents for these clinical conditions.
Waldmann
T A
TA
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
D001327:Autoimmune Diseases / Q000628:therapy*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007167:Immunotherapy; D007938:Leukemia / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis / Q000276:immunology*
D015375:Receptors, Interleukin-2